A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs TTI 622 (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Nivolumab; Pembrolizumab; Rituximab
- Indications Lymphoma; Multiple myeloma
- Focus Adverse reactions
- Sponsors Trillium Therapeutics Inc
- 14 Jun 2018 According to a Trillium Therapeutics media release, dosing has been initiated.
- 22 May 2018 Status changed from planning to recruiting.
- 10 Apr 2018 According to a Trillium Therapeutics media release, the first patient expected to be dosed in Q2 2018.